Shares of Chimerix Inc. (NASDAQ:CMRX) traded down 2.1% during mid-day trading on Tuesday . The stock traded as low as $4.49 and last traded at $4.56, with a volume of 130,484 shares trading hands. The stock had previously closed at $4.66.

Several analysts have issued reports on the company. FBR & Co restated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 target price on shares of Chimerix in a research note on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $16.18.

The company has a 50-day moving average of $4.07 and a 200-day moving average of $5.02. The firm’s market capitalization is $208.43 million.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.12. The business earned $1.80 million during the quarter, compared to analysts’ expectations of $1.98 million. On average, equities analysts predict that Chimerix Inc. will post ($1.81) EPS for the current year.

In other news, Director Ernest Mario acquired 50,000 shares of Chimerix stock in a transaction that occurred on Friday, June 24th. The stock was bought at an average price of $3.70 per share, for a total transaction of $185,000.00. Following the completion of the transaction, the director now owns 381,440 shares in the company, valued at $1,411,328. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO M Michelle Berrey acquired 13,188 shares of Chimerix stock in a transaction that occurred on Friday, June 24th. The shares were purchased at an average price of $3.69 per share, with a total value of $48,663.72. Following the transaction, the chief executive officer now owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Trexquant Investment LP boosted its position in shares of Chimerix Inc. (NASDAQ:CMRX) by 453.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 131,184 shares of the biopharmaceutical company’s stock after buying an additional 107,484 shares during the period. Trexquant Investment LP owned approximately 0.28% of Chimerix worth $1,174,000 at the end of the most recent reporting period.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.